JP2013511557A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511557A5
JP2013511557A5 JP2012540161A JP2012540161A JP2013511557A5 JP 2013511557 A5 JP2013511557 A5 JP 2013511557A5 JP 2012540161 A JP2012540161 A JP 2012540161A JP 2012540161 A JP2012540161 A JP 2012540161A JP 2013511557 A5 JP2013511557 A5 JP 2013511557A5
Authority
JP
Japan
Prior art keywords
daptomycin
solid medicinal
aqueous
composition
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012540161A
Other languages
English (en)
Japanese (ja)
Other versions
JP6041673B2 (ja
JP2013511557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057910 external-priority patent/WO2011063419A2/en
Publication of JP2013511557A publication Critical patent/JP2013511557A/ja
Publication of JP2013511557A5 publication Critical patent/JP2013511557A5/ja
Application granted granted Critical
Publication of JP6041673B2 publication Critical patent/JP6041673B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012540161A 2009-11-23 2010-11-23 リポペプチド組成物および関連する方法 Active JP6041673B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23
US61/263,784 2009-11-23
PCT/US2010/057910 WO2011063419A2 (en) 2009-11-23 2010-11-23 Lipopeptide compositions and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016039505A Division JP6088681B2 (ja) 2009-11-23 2016-03-02 リポペプチド組成物および関連する方法

Publications (3)

Publication Number Publication Date
JP2013511557A JP2013511557A (ja) 2013-04-04
JP2013511557A5 true JP2013511557A5 (https=) 2014-02-06
JP6041673B2 JP6041673B2 (ja) 2016-12-14

Family

ID=44060422

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012540161A Active JP6041673B2 (ja) 2009-11-23 2010-11-23 リポペプチド組成物および関連する方法
JP2016039505A Active JP6088681B2 (ja) 2009-11-23 2016-03-02 リポペプチド組成物および関連する方法
JP2017018290A Active JP6239167B2 (ja) 2009-11-23 2017-02-03 リポペプチド組成物および関連する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016039505A Active JP6088681B2 (ja) 2009-11-23 2016-03-02 リポペプチド組成物および関連する方法
JP2017018290A Active JP6239167B2 (ja) 2009-11-23 2017-02-03 リポペプチド組成物および関連する方法

Country Status (33)

Country Link
US (3) US8835382B2 (https=)
EP (2) EP2504353B2 (https=)
JP (3) JP6041673B2 (https=)
CN (3) CN102712677B (https=)
AR (2) AR079127A1 (https=)
AU (1) AU2010321531C1 (https=)
BR (1) BR112012012406B1 (https=)
CA (1) CA2781666C (https=)
CL (2) CL2012001336A1 (https=)
CO (1) CO6541585A2 (https=)
CR (1) CR20120271A (https=)
CY (1) CY1120854T1 (https=)
DK (1) DK2504353T4 (https=)
DO (1) DOP2012000140A (https=)
EC (1) ECSP12011939A (https=)
ES (1) ES2686331T5 (https=)
FI (1) FI2504353T4 (https=)
HR (1) HRP20181380T4 (https=)
HU (1) HUE039967T2 (https=)
IL (1) IL219891B (https=)
LT (1) LT2504353T (https=)
MX (1) MX2012005993A (https=)
NZ (1) NZ600118A (https=)
PE (2) PE20151717A1 (https=)
PL (1) PL2504353T5 (https=)
PT (1) PT2504353T (https=)
RS (1) RS57566B2 (https=)
RU (1) RU2607526C2 (https=)
SG (1) SG10201407724YA (https=)
SI (1) SI2504353T2 (https=)
TR (1) TR201812823T4 (https=)
TW (2) TWI606838B (https=)
WO (1) WO2011063419A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) * 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
US8709310B2 (en) 2011-01-05 2014-04-29 Hospira, Inc. Spray drying vancomycin
RU2013157188A (ru) * 2011-05-26 2015-07-10 Кьюбист Фармасьютикалз, Инк. Композиции св-183,315 и относящиеся к ним способы
CA2863291A1 (en) * 2012-01-12 2013-07-18 Celgene Corporation Romidepsin formulations and uses thereof
ES2655215T3 (es) * 2012-08-23 2018-02-19 Mylan Laboratories Ltd. Mejoramiento de la formulación inyectable de daptomicina
US9655946B2 (en) 2012-09-11 2017-05-23 Hospira Australia Pty Ltd. Daptomycin formulations and uses thereof
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
RU2770366C2 (ru) 2017-08-31 2022-04-15 Кселлия Фармасьютикалз Апс Препараты даптомицина
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
JP7582205B2 (ja) * 2019-12-26 2024-11-13 ニプロ株式会社 ダプトマイシンを含有する安定した凍結乾燥製剤
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
EP4117625A1 (en) * 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
SU1452484A3 (ru) 1984-10-09 1989-01-15 Эли Лилли Энд Компани (Фирма) Способ получени производных антибиотиков А-21978С, штамм стрептомицета SтRертомYсеS RoSeoSpoRUS, используемый дл получени антибиотических веществ А-21978С
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
IL93618A0 (en) * 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
DK0438813T3 (da) 1990-01-26 1998-07-27 Hoechst Ag Nyt antibiotikum, deoxymulundocandin, en fremgangsmåde til dets fremstilling samt dets anvendelse som lægemiddel
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (https=) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
DK0640095T3 (da) 1992-04-20 1999-04-12 Abbott Lab Fremgangsmåde til fremstilling af vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
PL203689B1 (pl) 1998-09-25 2009-11-30 Cubist Pharmaceuticals Zastosowanie daptomycyny
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2001044274A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
PL218223B1 (pl) * 2000-06-21 2014-10-31 Cubist Pharmaceuticals Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
MXPA04000747A (es) 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
KR20040032891A (ko) 2001-08-06 2004-04-17 큐비스트 파마슈티컬즈 인코포레이티드 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법
ATE325140T1 (de) 2002-01-17 2006-06-15 Arkema Supramolekularpolymere
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
JP2008546429A (ja) 2005-05-31 2008-12-25 キュービスト ファーマシューティカルズ， インコーポレイテッド バイオフィルム処理およびカテーテル救出のためのダプトマイシン
WO2007099396A2 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ES2401299T5 (es) * 2006-07-26 2016-04-06 Sandoz Ag Formulaciones de caspofungina
DK2084519T3 (da) 2006-10-10 2012-08-20 Los Alamos Nat Security Llc Røntgenfluorescens-analysefremgangsmåde
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
CA2692053A1 (en) 2007-06-26 2008-12-31 Merck Sharp & Dohme Corp. Lyophilized anti-fungal composition
AU2008317307A1 (en) * 2007-10-25 2009-04-30 Novartis Ag Powder conditioning of unit dose drug packages
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
WO2011035108A1 (en) 2009-09-17 2011-03-24 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2011062676A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
RU2607526C2 (ru) 2009-11-23 2017-01-10 Кьюбист Фармасьютикалз ЭлЭлСи Липопептидные композиции и родственные способы
CN103379917B (zh) 2010-11-01 2016-10-12 梅琳塔治疗公司 药物组合物
US20120202823A1 (en) 2010-12-23 2012-08-09 Alkermes, Inc. Multi-API Loading Prodrugs
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法

Similar Documents

Publication Publication Date Title
JP2013511557A5 (https=)
JP6239167B2 (ja) リポペプチド組成物および関連する方法
JP7229999B2 (ja) ダプトマイシン製剤
Murugappan et al. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants
EP2094308B1 (en) Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
WO2009046824A3 (en) Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis
WO2009033718A3 (en) Use of anti -inflammatory peptide 1 as a therapeutic agent
JP2005511642A (ja) セファロスポリン化合物を含む処方物ならびにイヌおよびネコにおける細菌感染の治療におけるその使用
WO2009039988A3 (en) Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
JP2013532729A5 (https=)
HU228296B1 (en) Compositions comprising antifungal agent and acetate buffer and their use
WO2009033660A3 (en) Use of octreotide as a therapeutic agent
CN104352454A (zh) 注射用夫西地酸钠粉针剂药物组合物和制法
WO2017085696A1 (en) Parenteral formulations of melphalan
WO2009033656A3 (en) Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
CA3139341A1 (en) Stable albuvirtide compositions
CN115038431B (zh) 达托霉素制剂
JP2014515371A5 (https=)
JP7720391B2 (ja) フォスフェニトインナトリウム固体組成物、凍結乾燥法、及びその使用
JP3935539B2 (ja) フマル酸ケトチフェン含有医薬組成物
CN108289840A (zh) 用于静脉内注射Danirixin的制剂
CN114588116A (zh) 磷苯妥英钠固体组合物、冻干方法、及其用途
JP2023510258A5 (https=)
JP2006117704A5 (https=)
HK40025124B (zh) 注射用组合物